in Health care
AbbVie plan to withdraw accelerated nods of Imbruvica in US for patients with certain types of blood cancer
North Chicago: AbbVie has announced the intent to voluntarily withdraw, in the U.S., accelerated IMBRUVICA (ibrutinib) approvals for patients with the blood cancers mantle cell lymphoma (MCL) who have received at least one prior therapy and with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy. Other […] More
